Reversible Cabozantinib-Induced Cardiomyopathy

Muhammad Alhussein; Sebastien J Hotte; Darryl P Leong

doi:10.1016/j.cjca.2018.12.025

Reversible Cabozantinib-Induced Cardiomyopathy

Can J Cardiol. 2019 Apr;35(4):544.e1-544.e2. doi: 10.1016/j.cjca.2018.12.025. Epub 2018 Dec 29.

Authors

Muhammad Alhussein¹, Sebastien J Hotte², Darryl P Leong³

Affiliations

¹ The Division of Cardiology, Department of Medicine, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
² Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada.
³ The Division of Cardiology, Department of Medicine, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada; The Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada. Electronic address: leongd@phri.ca.

PMID: 30935646
DOI: 10.1016/j.cjca.2018.12.025

Abstract

Cabozantinib is a multitargeted tyrosine kinase inhibitor, with activity against vascular endothelial growth factor receptor, as well as MET, RET, and AXL. It is currently approved for treating advanced thyroid and kidney cancers, and is being investigated in other cancers. We present a case of reversible heart failure due to cabozantinib use in a 70-year-old man with metastatic renal cell carcinoma. This is, to our knowledge, one of the first reported cases of cardiomyopathy associated with cabozantinib use.

Publication types

Case Reports
Research Support, Non-U.S. Gov't
Video-Audio Media

MeSH terms

Aged
Anilides / adverse effects*
Carcinoma, Renal Cell / drug therapy
Heart Failure / chemically induced*
Humans
Kidney Neoplasms / drug therapy
Lung Neoplasms / drug therapy
Lung Neoplasms / secondary
Male
Protein Kinase Inhibitors / adverse effects*
Pyridines / adverse effects*
Ventricular Dysfunction, Left / chemically induced*

Substances

Anilides
Protein Kinase Inhibitors
Pyridines
cabozantinib